|Dr. Peter D. Suzdak||Chief Exec. Officer and Director||594.51k||N/A||58|
|Dr. Ely Benaim M.D.||Chief Medical Officer||608.98k||N/A||56|
|Dr. Lisa Elizabeth Nolan Ph.D.||Chief Bus. Officer||206.76k||N/A||55|
|Mr. Douglas J. Swirsky||Pres & CFO||N/A||N/A||48|
|Dr. Reza Mazhari Ph.D.||VP of Translational Medicine||N/A||N/A||N/A|
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.
Rexahn Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.